Ultragenyx reported failure of two phase 3 trials in brittle-bone disease and said it will execute significant cost reductions. The company will reassess its pipeline priorities and implement spending cuts to preserve capital after the late-stage setbacks. Management framed the move as necessary to rebalance the portfolio and extend the company’s operating runway, while investors and collaborators will watch for guidance on which programs are retained or deprioritized going forward.